Patents Examined by L. Blaine Lankford
-
Patent number: 7507558Abstract: The present invention provides a method of producing inulin by bringing inulin synthase into contact with sucrose, wherein: (1) the average polymerization degree of inulin is regulated by controlling the sucrose concentration; (2) the average polymerization degree of inulin is regulated by controlling the temperature upon the above contact; and/or (3) at a stage when the above sucrose is consumed by the above inulin synthase and the reaction reaches an equilibrium state, sucrose is additionally added, and the reaction for generating inulin is further continued. Furthermore, the present invention relates to inulin having a predetermined average polymerization degree, which is obtained by the production method.Type: GrantFiled: September 26, 2002Date of Patent: March 24, 2009Assignee: Fuji Nihon Seito CorporationInventors: Tadashi Wada, Masao Ohguchi
-
Patent number: 7504115Abstract: Disclosed is a composition from shark cartilage comprising immunoactive proteoglycans and other immunoactive components having a molecular weight greater than about 100 KD, wherein the composition has a uronic acid content of about 0.05-0.5 ?g glucuronic acid per ?g of the composition. The composition may be useful for treating or preventing tumor growth, bacterial infections, viral infections and/or fungal infections.Type: GrantFiled: February 15, 2002Date of Patent: March 17, 2009Assignee: Ocean Nutrition Canada LimitedInventors: Jaroslav A. Kralovec, Frank Chung-Yin Sing
-
Patent number: 7476257Abstract: The present invention is directed to a cultured, stratified cartilage tissue that comprises a tissue-engineered, cohesive cartilage construct comprised of two or more cartilage layers, wherein each cartilage layer comprises chondrogenic cells having a chondrocytic phenotype corresponding to chondrocytes present in: a superficial-tangential zone of natural cartilage; a middle-transitional zone of natural cartilage; a deep-radial zone of natural cartilage; or a calcified cartilage zone of natural cartilage.Type: GrantFiled: September 13, 2002Date of Patent: January 13, 2009Assignees: Rush University Medical Center, The Regents of the University of CaliforniaInventors: Robert L. Sah, Kelvin W. Li, Travis J. Klein, Barbara L. Schumacher, Koichi Masuda, Eugene J-M. A. Thonar
-
Patent number: 7435587Abstract: This invention provides an apparatus for growing cells under static or dynamic physiological pressure which contains a cell culture cassette having a cassette frame; two side walls secured to each side of the cassette frame to form a cell growing chamber, and at least one side wall comprises a cell growth surface. The apparatus also contains a means for adjusting fluid pressure or flow, for providing culture media or cell culture, or for sampling cell culture or culture media within the cell growing chamber. The apparatus further contains an adapter which contains two side assemblies where each side assembly includes a frame with a rigid support that fits over the cell culture cassette. The side assemblies joined by a hinge at one end and positioned over the two side walls of the cell culture cassette. The apparatus further contains a means to secure the two side assemblies over the two side walls of the cell culture cassette.Type: GrantFiled: December 20, 2004Date of Patent: October 14, 2008Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Gene R. Diresta, John H. Healey, Robert Schwar
-
Patent number: 7435411Abstract: The present invention relates to a paecilomyces genus microorganism and microbial insecticide for controlling the soil pests using the same, more particularly to a paecilomyces genus microorganism having insecticidal activity to soil pests and a microbial insecticide for controlling the soil pests containing the same. Since the microbial insecticide of the present invention shows excellent insecticidal activity to harmful soil pests, it can effectively be used as a environment-compatible insecticide to prevent the soil pests from farmland crops.Type: GrantFiled: November 2, 2002Date of Patent: October 14, 2008Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Ho Yong Park, Kwang Hee Son, Eun Young Suh, Ki-Duk Kim, Dong Ha Shin
-
Patent number: 7429488Abstract: Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.Type: GrantFiled: July 7, 2003Date of Patent: September 30, 2008Assignee: Cytori Therapeutics, Inc.Inventors: John K. Fraser, Marc H. Hedrick
-
Patent number: 7422900Abstract: A system and method are provided for forming a connective tissue construct, such as a tendon construct, in vitro. A substrate is provided with at least two anchors secured thereto in spaced relationship. Fibroblast cells are provided on the substrate in the absence of a synthetic matrix, where at least some of the cells are in contact with the anchors. The cells are cultured in vitro under conditions to allow the cells to self-organize and become confluent between the anchors, where the anchors are receptive to the cells and allow the cells to attach thereto while permitting the cells to detach from the substrate to form a three-dimensional connective tissue construct.Type: GrantFiled: June 24, 2003Date of Patent: September 9, 2008Assignee: The Regents of the University of MichiganInventors: Paul E. Kosnik, Robert G. Dennis, Sarah C. Calve, Ellen M. Arruda
-
Patent number: 7419661Abstract: The invention concerns the use of dermal sheath tissue and/or cells derived therefrom in wound healing systems. Specifically, the relevant features of this tissue type have been exploited to provide a novel wound healing material that has application in the provision of new therapeutic compositions and new surgical dressings where wound closure and minimal scarring is desirable.Type: GrantFiled: March 24, 2003Date of Patent: September 2, 2008Assignee: The Centre of Excellence for Life Sciences LimitedInventors: Amanda Jane Jahoda, Colin Albert Buchanan Jahoda
-
Patent number: 7419817Abstract: The present invention provides methods of purifying adeno-associated virus (AAV) particles. These AAV particles include AAV2, AAV4 and AAV5 particles. The present invention also provides AAV particles purified by the methods of the present invention.Type: GrantFiled: May 17, 2002Date of Patent: September 2, 2008Assignee: The United States of America as represented by the Secretary Department of Health and Human Services, NIH.Inventors: John A. Chiorini, Nikola A. Kaludov
-
Patent number: 7402435Abstract: A method of highly efficiently transferring various selected molecules into various cells and a method of fusing cells. Cells and/or selected molecules such as polynucleotide are treated with cold gas plasma to thereby transfer the selected molecules located around cells into the cells, or cells are fused by treating the cells with cold gas plasma. Moreover, an apparatus for transferring selected molecules or fusing cells having a cold gas plasma generation unit for transferring selected molecules into cells is provided.Type: GrantFiled: February 8, 2002Date of Patent: July 22, 2008Assignees: BBK Bio Corporation, Pearl Kogyo Co., Ltd.Inventors: Sousuke Miyoshi, Akiko Ohkubo, Noriyuki Morikawa, Yasuhiro Ogawa, Shintaro Nishimura, Masao Fukagawa, Hiroyuki Arakawa, Jyunko Zenkou, Susumu Sato
-
Patent number: 7393841Abstract: The invention relates to the use of hyperbranched amylopectin which has an average branch degree of between >10 and 25 mol % and a molecular weight (Mw) ranging from 40.000-800.000 Dalton and the derivatives thereof in methods for surgical or therapeutic treatment of human or animal bodies or in a diagnostic method, preferably as a plasma volume expander. Plasma volume expanders based on hydroxy-ethylated amylopectin have, as a result of hydroxy ethylation, hitherto exhibited the disadvantage of incomplete metabolism and thus temporary tissue storage which is linked to side-effects. According to the invention, novel plasma expanders based on polysaccharides which do not exhibit the same disadvantages as the former are provided.Type: GrantFiled: August 6, 2002Date of Patent: July 1, 2008Assignee: Supramol Parenteral Colloids GmbHInventor: Klaus Sommermeyer
-
Patent number: 7390484Abstract: Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.Type: GrantFiled: July 7, 2003Date of Patent: June 24, 2008Assignee: Cytori Therapeutics, Inc.Inventors: John K. Fraser, Marc H. Hedrick
-
Patent number: 7381427Abstract: The subject of the present invention is seborrheic keratosis removal and prevention utilizing safe dependable effective biocompatible treatments with no scarring, bleeding, burning, freezing, shocking, and hypopigmentation or hyperpigmentation.Type: GrantFiled: October 9, 2003Date of Patent: June 3, 2008Inventors: Margaret Ancira, Mickey Miller
-
Patent number: 7294334Abstract: Methods, devices, kits and compositions to treat a myocardial infarction. In one embodiment, the method includes the prevention of remodeling of the infarct zone of the ventricle using a combination of therapies. The method may include the introduction of structurally reinforcing agents. In other embodiments, agents may be introduced into a ventricle to increase compliance of the ventricle. The prevention of remodeling may include the prevention of thinning of the ventricular infarct zone. Another embodiment includes the reversing or prevention of ventricular remodeling with electro-stimulatory therapy. The unloading of the stressed myocardium over time effects reversal of undesirable ventricular remodeling. These therapies may be combined with structurally reinforcing therapies. In other embodiments, the structurally reinforcing component may be accompanied by other therapeutic agents. These agents may include but are not limited to pro-fibroblastic and angiogenic agents.Type: GrantFiled: March 16, 2004Date of Patent: November 13, 2007Assignee: Advanced Cardiovascular Systems, Inc.Inventors: Eugene T. Michal, Jeffrey Ross
-
Patent number: 7294352Abstract: Active enamel substances may be used for the preparation of a pharmaceutical or cosmetic composition for healing of a wound, improving healing of a wound, soft tissue regeneration or repair, or for preventing or treating infection or inflammation.Type: GrantFiled: October 30, 2003Date of Patent: November 13, 2007Assignee: Biora BioEx ABInventors: Stina Gestrelius, Lars Hammarström, Petter Lyngstadaas, Christer Andersson, Ivan Slaby, Tomas Hammargren
-
Patent number: 7291500Abstract: In order to grow an object to be cultivated or grown, a growth object is encapsulated in a vessel, and the growth object is grown without substantial influence of gravity.Type: GrantFiled: May 18, 2005Date of Patent: November 6, 2007Assignees: Mitsubishi Heavy Industries, Ltd.Inventors: Masaru Uemura, Jun-ichiro Gyotoku, Makoto Asashima
-
Patent number: 7241730Abstract: Heparin-binding regions of several proteins, such as neural cell adhesion molecule, fibronectin, laminin, midkine, and anti-thrombin III have been shown to promote neurite extension on two-dimensional surfaces. The effect of heparin-binding peptides on neurite extension through three-dimensional matrices was investigated by culturing embryonic chick dorsal root ganglia (DRG) within fibrin gels containing chemically attached heparin-binding peptide (HBP). The length of neurites within fibrin gels containing cross-linked HBP was increased by more than 70% over extension through fibrin gels containing no peptide. The HBP sequence of antithrombin III was incorporated into the fibrin gel as the C-terminal domain of a bidomian, chimeric peptide; the N-terminal second domain of this peptide contained the ?2-plasmin inhibitor substrate for Factor XIIIa. Factor XIIIa, a transglutaminase, was used to chemically attach the HBP-containing chimeric peptide to the fibrin gels during polymerization.Type: GrantFiled: March 25, 2002Date of Patent: July 10, 2007Assignees: Universitat Zurich, Eidgenossische Technische Hochschule ZurichInventors: Jeffrey A. Hubbell, Jason C. Schense, Shelly E. Sakiyama
-
Patent number: 7229810Abstract: Methods are provided for the stabilization of proteinases by the covalent attachment of or admixture with water-soluble polymers. The resultant stabilized proteinases have increased stability under the harsh conditions used in industrial genomics, which permits their use in the extraction and isolation of nucleic acids and the identification of disease-related prion proteins at elevated temperatures in solutions containing chaotropic agents, such as sodium dodecyl sulfate, urea or guanidinium salts, conferring advantages for robotic applications.Type: GrantFiled: June 28, 2002Date of Patent: June 12, 2007Assignee: Mountain View Pharmaceuticals, Inc.Inventors: Merry R. Sherman, Alexa L. Martinez, Shyam S. Bhaskaran, L. David Williams, Mark G. P. Saifer, John A. French
-
Patent number: 7226760Abstract: Disclosed are a fluid absorber, a method for preparing a fluid absorber, and a method for absorbing fluid from the skin. The disclosed method for preparing a fluid absorber generally comprises the steps of selecting a starch and an enzyme for hydrolysis of the starch, determining a fluid absorption optimum hydrolysis level for the starch, and ezymatically hydrolyzing the starch to approximately the optimum level thus determined. The starch alternatively may be hydrolyzed with acid hydrolysis without the use of an enzyme catalyst. The disclosed method for absorbing fluid from the skin includes the step of applying a fluid absorbing effective amount of a fluid absorber thus prepared. Absorption properties of the fluid absorber of the invention are comparable to or exceed those of commercially available skin fluid absorbers, such as talc and unmodified corn starch.Type: GrantFiled: June 11, 2003Date of Patent: June 5, 2007Assignee: Grain Processing CorporationInventors: Hélène G. Bazin, Frank W. Barresi
-
Patent number: RE39792Abstract: A biochemically defined culture medium for culturing engineered Chinese hamster ovary (CHO) cell lines, which is essentially free from protein, lipid and carbohydrate isolated from an animal source, having water, an osmolality regulator, a buffer, an energy source, amino acids including L-glutamine, an inorganic or recombinant iron source, and a synthetic or recombinant growth factor, and optionally non-ferrous metal ions vitamins and cofactors. Also cells adapted to grow in such a culture medium. REEXAMINATION RESULTS The questions raised in reexamination request no. 90/006656, filed Jun. 2, 2003 have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e), for ex parte reexaminations, or the reexamination certificate required by 35 U.S.C. 316 as provided in 37 CFR 1.997(e) for inter partes reexaminations.Type: GrantFiled: November 22, 2004Date of Patent: August 21, 2007Assignee: SmithKline Beecham CorporationInventors: Michael J. Keen, Nicholas T. Rapson